Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QT WiST analysis from the CELESTIAL study

Category Primary study
ConferenceAnnals of Oncology
Year 2019
This article has no abstract
Epistemonikos ID: 08e24fa5921dd58ead41799136848332481c1eb9
First added on: Feb 11, 2025